Small molecules that inhibit the Menin-MLL1 interaction provide promising therapeutic opportunities for acute leukemias with MLL1-r or NPM1c; several such small molecules, including DS-1594b, have entered clinical trials [41]. The gene discussed is MEN1; the disease is acute leukemia.